I'm a board-certified child neurologist who specializes in neuromuscular diseases. I am co-director of the multidisciplinary comprehensive neuromuscular care program and serve as the program's neurology lead. I'm also the clinical director of the Parent Project Muscular Dystrophy (PPMD) Certified Duchenne Muscular Dystrophy (DMD) Clinic and clinical director of the Muscular Dystrophy Association (MDA) Care Center.
My mom was a devoted elementary teacher, loved by many of her students. Her love for children inspired me, and I became a pediatrician. I am honored to be recognized by Cincinnati Magazine’s Top Doctors in Pediatric Neurology (2023).
I'm passionate about caring for children and young adults with chronic neuromuscular disease. I love meeting families and listening to parents advocating for their children. My team and I are focused on families' concerns and work together to provide the best care possible to our patients.
As a clinical researcher, I actively lead and collaborate on multiple clinical trials and research studies in pediatric neuromuscular diseases to develop advanced therapies and improve clinical care for our patients.
When I'm not at work, I love music and the arts. I also enjoy gardening and playing tennis.
MD: Medical Center of Fudan University, Shanghai, China, 1993
Residency: Cincinnati Children’s Hospital Medical Center
Myology Institute Clinical Myology Training: Paris, France, 2014
Wellstone Myology Training: Ohio State University, Columbus, OH, 2013
World Muscle Society Satellite Training: Asilomar, CA, 2013
Cincinnati Children's strives to accept a wide variety of health plans. Please contact your health insurance carrier to verify coverage for your specific benefit plan.
Optimizing Care for Growth and Puberty in Duchenne Muscular Dystrophy: A Survey of Clinical Practice in the OPTIMIZE DMD Consortium. Muscle and Nerve. 2026; 74(2):433-439.
Fatal Fat Embolism Syndrome Without Recognized Fracture in Patients With Duchenne Muscular Dystrophy: Two Case Reports. Pediatric Neurology. 2026; 181:51-55.
From case to caution: hyponatremia in a patient with Duchenne muscular dystrophy on vamorolone and lessons for clinicians. Neuromuscular Disorders. 2026; 62:106411.
Advancements from the EVOLVE study for assessing real-world experience with eteplirsen, golodirsen and casimersen for the treatment of DMD. Journal of Comparative Effectiveness Research. 2026; 15(5):e250108.
The burden of bone disease in Duchenne muscular dystrophy: age-specific prevalence of osteoporosis and low bone density. Osteoporosis International. 2026.
Acute Adverse Events Following Intravenous Bisphosphonate Infusion Are Uncommon in Patients With Duchenne Muscular Dystrophy Previously Treated With Oral Bisphosphonates. Muscle and Nerve. 2026; 73(3):445-451.
Reclassification of intragenic DMD gene duplications by optical genome mapping resolves uncertainty and improves clinical management. Neuromuscular Disorders. 2026; 60:106335.
Treatment advances for Duchenne muscular dystrophy. Current Opinion in Pediatrics. 2026.
Adrenal Suppression in Duchenne Muscular Dystrophy: Management Strategies Incorporating Novel Steroid Vamorolone. Journal of the Endocrine Society. 2026; 10(2):bvaf181.
Elevated Levels of Active GSK3β in the Blood of Patients with Myotonic Dystrophy Type 1 Correlate with Muscle Weakness. International Journal of Molecular Sciences. 2025; 26(21).
Patient Ratings and Comments
All patient satisfaction ratings and comments are submitted by actual patients and verified by a leading independent experience management company, Qualtrics. Patient identities are withheld to ensure confidentiality and privacy. Only those providers whose satisfaction surveys are administered through Cincinnati Children’s Hospital Medical Center are displayed. Click here to learn more about our survey